ERBB2 and breast cancer: The exploratory analysis of the MA.32 trial in the HER2+ population was informed by the METTEN study [3], a phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in early HER2+ BC conducted by us in 2018.